S. Weitman

发表

Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues.

L R Coney, V. Zurawski, S. Weitman, 1992, Cancer research.

Biodegradable block copolymers for delivery of proteins and water-insoluble drugs.

J. Mestecky, Z. Moldoveanu, J Mestecky, 2001, Journal of controlled release : official journal of the Controlled Release Society.

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study

I. Flinn, A. Freedman, A. Stathis, 2018, Investigational New Drugs.

Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.

W. R. Bishop, D. V. Von Hoff, T. Petit, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer

T. Huang, P. Osmulski, M. Gaczynska, 2020, Cancer Research.

Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature.

W. Bellini, C. Timmons, N. Winick, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.

E K Rowinsky, S G Hilsenbeck, D. V. Von Hoff, 2000, European journal of cancer.

Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts

E. Izbicka, S. Weitman, E. V. Van Laar, 2003, International Journal of Gynecologic Cancer.

Single‐cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT‐related genes in metastatic prostate cancer

I. Thompson, Luzhe Sun, T. Huang, 2013, The Prostate.

A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.

A. Kraft, M. Bernstein, R. Berkow, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The folate receptor in central nervous system malignancies of childhood

S. Weitman, B. Kamen, K. M. Frazier, 2005, Journal of Neuro-Oncology.

Folate receptor imaging with 125I labeled folic acid with a whole body small animal imaging device built with plastic scintillating optical fibers

John O. Prior, Johann L. Fernando, Jon A. Anderson, 1995 .

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay

D. V. Von Hoff, S. Hilsenbeck, C. Britten, 1999, Cancer Chemotherapy and Pharmacology.

Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.

D. V. Von Hoff, G. Mangold, P. Potter, 1999, Cancer research.

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.

R. Arceci, P. Steinherz, P. Gaynon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Development of a Minority Recruitment Plan for Cancer Clinical Trials.

I. Thompson, B. Pollock, A. Ramirez, 2013, Journal of community medicine & health education.

Phase I Trial of Rebeccamycin Analog (NSC #655649) in Children With Refractory Solid Tumors: A Pediatric Oncology Group Study

S. Baruchel, S. Weintraub, M. Bernstein, 2003, Journal of pediatric hematology/oncology.

Pediatric Phase II Cancer Chemotherapy Trials: A Pediatric Oncology Group Study

J. Shuster, N. Winick, C. Pratt, 1997, Journal of pediatric hematology/oncology.

Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?

J. Michalek, D. Mahalingam, B. Hernandez, 2014, Investigational New Drugs.

High-dose methotrexate: is it warranted?

S. Weitman, B. Kamen, 1994, Pediatric hematology and oncology.

Accumulation of 5‐methyltetrahydrofolic acid and folylpolyglutamate synthetase expression by mitogen stimulated human lymphocytes

S. Weitman, R. Lark, D. Fort, 1993, British journal of haematology.

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days1, 3, and 5 Every 3 Weeks in Patientswith Advanced Solid Tumors

P. Bonate, D. Ryan, L. Appleman, 2005 .

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

P. Bonate, D. Ryan, L. Appleman, 2005, Clinical Cancer Research.

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.

S. Sleijfer, P. Rutkowski, P. Hohenberger, 2014, European journal of cancer.

Antitumor activity of a kinesin inhibitor.

K. Wood, J. Finer, J. Mak, 2004, Cancer research.

Formulation and device design to increase nose to brain drug delivery

Alan B. Watts, H. Smyth, R. Williams, 2016 .

Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies.

D. V. Von Hoff, M. Zasloff, K. Holroyd, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

New drug development for pediatric oncology

C. Pratt, S. Weitman, L. Carlson, 2004, Investigational New Drugs.

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

P. Bonate, G. Weiss, A. Mita, 2006, Clinical Cancer Research.

Increasing Applied Skills in an Introductory Marketing Course

S. Weitman, R. Bell, 1995 .

Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia.

S. Corey, L. Robinson, F. Goldman, 2005, Journal of pediatric hematology/oncology.

Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.

M. Relling, Y. Ravindranath, C. Pratt, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system.

D. V. Von Hoff, S. Hilsenbeck, E. Izbicka, 1999, Anti-cancer drugs.

Anemia and hepatosplenomegaly as presenting features in a child with rickets and secondary myelofibrosis.

T. DeNapoli, S. Weitman, A. Langevin, 2003, Journal of pediatric hematology/oncology.

Phase I Trial and Pharmacokinetic Study of Raltitrexed in Children with Recurrent or Refractory Leukemia: A Pediatric Oncology Group Study

M. Bernstein, T. Horton, S. Berg, 2005, Clinical Cancer Research.

Discovery and development of clofarabine: a nucleoside analogue for treating cancer

P. Bonate, S. Weitman, J. Secrist, 2006, Nature Reviews Drug Discovery.

A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors

P. Bonate, E. Hersh, L. Hammond, 2005, Clinical Cancer Research.

APhase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3Weeks in Patientswith Advanced SolidTumors

P. Bonate, E. Hersh, L. Hammond, 2005 .

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors

N. Senzer, J. Nemunaitis, D. Mahalingam, 2014, Cancer Chemotherapy and Pharmacology.

The complete phase Ib clinical trial: A method to accelerate new agent development

D. V. Hoff, E. Cvitkovic, S. Weitman, 2007 .

Determination of in utero fetal rat heart rate by ultrasound.

S. Weitman, K. C. Preuss, 1987, Journal of pharmacological methods.

A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.

M. Bernstein, C. Pratt, S. Berg, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Eligibility of patients with renal impairment for Phase I trials: Time for a rethink?

S. Weitman, L. Malik, A. Mejia, 2014, European journal of cancer.

Hepatocellular Carcinoma in Children Associated With Gardner Syndrome or Familial Adenomatous Polyposis

T. DeNapoli, S. Weitman, L. Bowman, 1998, Journal of pediatric hematology/oncology.

Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor

D. A. Bush, R. Quigley, S. Weitman, 1997, Cancer Chemotherapy and Pharmacology.

Promoting Factors and Barriers to Participation in Early Phase Clinical Trials: Patients Perspectives.

B. Pollock, P. Chalela, A. Ramirez, 2014, Journal of community medicine & health education.

Elevated expression of DNA ligase I in human cancers.

D. Sun, J. Marty, S. Weitman, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel

D. Kufe, S. Kharbanda, M. Bamberg, 2005, Cancer Chemotherapy and Pharmacology.

The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.

Haiyong Han, D. V. Von Hoff, D. Bearss, 2002, Molecular cancer therapeutics.

Preclinical Antitumor Activity and Pharmacokinetics of Methyl-2-Benzimidazolecarbamate (FB642)

D. V. Von Hoff, G. Mangold, D. Dexter, 2002, Investigational New Drugs.

Propranolol-induced alterations in rat erythrocyte membrane fluidity and apparent phase-transition temperatures. A depth-dependent process.

D. Lange, A. Phelan, J. Lech, 1989, Biochemical pharmacology.

Exploring the mechanisms of action of FB642 at the cellular level

D. V. Von Hoff, L. Hammond, E. Izbicka, 2001, Journal of Cancer Research and Clinical Oncology.

The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.

D. V. Von Hoff, J. Jolivet, J. Marty, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo.

S. Weitman, E. V. Van Laar, Stephanie Roth, 2004, Anticancer research.

AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients

Cesario Z. Cerna, S. Weitman, L. Gomez, 2003, Anti-cancer drugs.

WTAP is a novel oncogenic protein in acute myeloid leukemia

G E Tomlinson, U. Suresh, L. Penalva, 2014, Leukemia.

A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier

Daniel A. Davis, Yajie Zhang, H. Smyth, 2018, Pharmaceutics.

Combined venetoclax and alvocidib in acute myeloid leukemia

R. Mesa, D. Bearss, C. Shi, 2017, Oncotarget.

A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors.

L. Frankel, N. Vapiwala, N. Winick, 2001, Medical and pediatric oncology.

The Cationic Porphyrin TMPyP 4 Down-Regulates c-MYC and Human Telomerase Reverse Transcriptase Expression and Inhibits Tumor Growth in Vivo 1

D. Bearss, D. V. Hoff, L. Hurley, 2002 .

Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes

E. Stuart, I. Thompson, A. Ramirez, 2016, Cancer Prevention Research.

Single‐cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT‐related genes in metastatic prostate cancer

I. Thompson, Luzhe Sun, T. Huang, 2013, The Prostate.

The folate receptor as a potential therapeutic anticancer target

S. Weitman, B. A. Gruner, 1998, Investigational New Drugs.

Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim liposomes in nude mice.

Hong Wong, Lee Jia, L. Jia, 2002, Journal of pharmaceutical and biomedical analysis.

Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.

M. Bernstein, C. Pratt, H. Grier, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential toxicity of trans-permethrin in rainbow trout and mice. I. Role of biotransformation.

J. Lech, S. Weitman, A. Glickman, 1982, Toxicology and applied pharmacology.

Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

L. Ellis, C. Liang, J. Cherrington, 2000, Anti-cancer drug design.

Population Pharmacokinetics of Clofarabine, a Second‐Generation Nucleoside Analog, in Pediatric Patients With Acute Leukemia

P. Bonate, W. Plunkett, V. Gandhi, 2004, Journal of clinical pharmacology.

Pediatric Phase I Drug Tolerance: A Review and Comparison of Recent Adult and Pediatric Phase I Trials

Malcolm A. Smith, S. Weitman, L. Carlson, 1996, Journal of pediatric hematology/oncology.

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.

P. Bonate, J. Kuhlmann, D. Mould, 2007, British journal of clinical pharmacology.

Phase 1 Study of Paclitaxel Administered Twice Weekly to Children With Refractory Solid Tumors: A Pediatric Oncology Group Study

M. Bernstein, T. Vietti, S. Weitman, 2003, Journal of pediatric hematology/oncology.

Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony‐forming units, and xenografts

E. Izbicka, S. Weitman, E. V. Van Laar, 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

In Vitro Antitumor Activity of Rebeccamycin Analog (NSC# 655649) Against Pediatric Solid Tumors

D. V. Von Hoff, N. Cheung, E. Izbicka, 1998, Journal of pediatric hematology/oncology.

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

S. Groshen, J. Friedberg, K. Venkatakrishnan, 2018, Clinical Cancer Research.

ZD0473 exhibits marked in vitro anticancer activity in human tumor specimens

Cesario Z. Cerna, T. Stephens, S. Weitman, 2001 .

An evaluation of elderly patients (≥70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011.

J. Michalek, M. Goros, J. Rowe, 2014, Journal of geriatric oncology.

Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study.

P. Bonate, N. Winick, M. Bernstein, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-dose methotrexate therapy for hepatoblastoma

S. Weitman, B. Kamen, J. Barbosa, 2004, Cancer Chemotherapy and Pharmacology.

Enhancement of DNA ligase I level by gemcitabine in human cancer cells.

S. Weitman, S. Kelly, Daekyu Sun, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.

E K Rowinsky, S G Hilsenbeck, D. V. Von Hoff, 1999, Cancer research.

Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.

D. V. Von Hoff, G. Clark, E. Rowinsky, 1999, Anti-cancer drugs.

Pharmacokinetic Evaluation of a New Oral Cyclosporine Formulation

R. Ausman, E. Sasse, S. Weitman, 1994, Pharmacotherapy.

Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer

P. Bonate, P. Steinherz, P. Gaynon, 2011, Cancer Chemotherapy and Pharmacology.

WTAP is a novel oncogenic protein in acute myeloid leukemia

U. Suresh, L. Penalva, D. Proia, 2014, Leukemia.

Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis.

V. Zurawski, A. Weinberg, S. Weitman, 1992, Cancer research.

Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft

D. V. Von Hoff, S. Hilsenbeck, G. Mangold, 1999, Cancer Chemotherapy and Pharmacology.

Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models

S. Weitman, E. V. Van Laar, S. Waters, 2004, The Prostate.

Liquid chromatography-mass spectrometry assay of a thiadiazole derivative in mice: application to pharmacokinetic studies.

S. Weitman, L. Jia, J. B. Camden, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies

R. Aguiar, J. Kuhn, S. Weitman, 2016, Clinical Cancer Research.

Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.

M. Hidalgo, D. V. Von Hoff, G. Clark, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MGI 114: augmentation of antitumor activity when combined with topotecan.

D. V. Von Hoff, S. Hilsenbeck, J. Marty, 2000, Journal of pediatric hematology/oncology.

Direct Raman imaging techniques for study of the subcellular distribution of a drug.

Jian Ling, Alan C Bovik, Michael A. Miller, 2002, Applied optics.

Effect of Nanonization on Absorption of 301029: Ex Vivo and In Vivo Pharmacokinetic Correlations Determined by Liquid Chromatography/Mass Spectrometry

Cesario Z. Cerna, L. Jia, S. Weitman, 2002, Pharmaceutical Research.

Overview of Oncology Drug Development

S. Weitman, L. Malik, 2016 .

Influence of pregnancy on parathion toxicity and disposition.

J. Lech, S. Weitman, M. Vodicnik, 1983, Toxicology and applied pharmacology.

Vitamin receptors: Folate binding proteins

Richard G. W. Anderson, S. Weitman, B. Kamen, 1994 .

Early Phase Clinical Trials: Referral Barriers and Promoters among Physicians.

B. Pollock, P. Chalela, A. Ramirez, 2012, Journal of community medicine & health education.

Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle.

L. Jia, S. Weitman, M. Garza, 2003, Journal of pharmaceutical sciences.

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study.

J. Blay, P. Hohenberger, H. Gelderblom, 2010 .

Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors

F. Caponigro, F. Fiorentini, S. Crippa, 2010, Cancer Chemotherapy and Pharmacology.

Personalized Medicine in Nasal Delivery: The Use of Patient-Specific Administration Parameters To Improve Nasal Drug Targeting Using 3D-Printed Nasal Replica Casts.

Daniel A. Davis, H. Smyth, R. Williams, 2018, Molecular pharmaceutics.

Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming units.

D. V. Von Hoff, T. Petit, E. Izbicka, 1999, Anti-cancer drugs.

Clofarabine administered weekly to adult patients with advanced solid tumors in a phase I dose-finding study

N. Senzer, J. Nemunaitis, C. Cunningham, 2004 .

Clofarabine administered weekly to adult patients with advanced solid tumors in a phase I dose-finding study.

N. Senzer, J. Nemunaitis, C. Cunningham, 2004, Journal of Clinical Oncology.

Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors.

L. C. Chen, F. Fossella, P. Lorigan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Title: Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type 2 Diabetes Running title: Metformin for Reducing Prostate Cancer Disparity

E. Stuart, I. Thompson, A. Ramirez, 2016 .

Predicting success in regulatory approval from Phase I results

Helen Parsons, Andrew Brenner, A. Brenner, 2014, Cancer Chemotherapy and Pharmacology.

Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib

D. Bearss, Adam Siddiqui-Jain, S. Warner, 2017 .

Phase I Therapy Trials in Children With Cancer

M. Bernstein, W. Furman, C. Pratt, 1998, Journal of pediatric hematology/oncology.

Back to the basics: the importance of concentration x time in oncology.

E. Glatstein, S. Weitman, B. Kamen, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM).

A. Chanan-Khan, S. Weitman, S. Ailawadhi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials.

B. Pollock, D. Mahalingam, N. Ketchum, 2014, Journal of gastrointestinal oncology.

A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

I. Flinn, A. Freedman, A. Stathis, 2014 .

Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).

A. Skotnicki, S. Weitman, V. Vukovic, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fosfomycin--friend or foe?

S. Weitman, B. Kamen, 1991, Pediatric hematology and oncology.